AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA,…
Pharmaceuticals, Biotechnology and Life Sciences
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA,…
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30…
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE)…
Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024 COPENHAGEN,…
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the…
BURR RIDGE, Ill., March 14, 2024 (GLOBE NEWSWIRE) — SkinCure Oncology, the world leader in providing a comprehensive model for…
Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure…
VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) — Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAF),…
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…